ВИЧ/СПИД: взгляд на проблему

DOI: https://doi.org/10.29296/25877305-2021-02-07
Скачать статью в PDF
Номер журнала: 
2
Год издания: 
2021

К.Р. Амлаев, доктор медицинских наук, профессор Ставропольский государственный медицинский
университет Минздрава России E-mail: kum672002@mail.ru

Статья в формате мини-лекции посвящена проблеме инфицирования вирусом иммунодефицита человека. Представлены данные об истории возникновения вируса в 20-х гг. прошлого века. Рассмотрены механизмы инфицирования, риски заражения вирусом посредством различных действий. Кратко описаны основные современные подходы к профилактике и лечению заболевания, приводится понятие стадии синдрома приобретенного иммунодефицита.
Ключевые слова: 
инфекционные заболевания
вирус иммунодефицита человека
синдром приобретенного иммунодефицита
медицинская профилактика
Для цитирования
К.Р. Амлаев ВИЧ/СПИД: взгляд на проблему . Врач, 2021; (2): 37-41 https://doi.org/10.29296/25877305-2021-02-07

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. Sharp P.M., Hahn B.H. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011; 1 (1): a006841. DOI: 10.1101/cshperspect.a006841
  2. Hymes K.B., Cheung T., Greene J.B. et al. Kaposi’s sarcoma in homosexual men-a report of eight cases. Lancet. 1981; 2 (8247): 598–600. DOI: 10.1016/s0140-6736(81)92740-9
  3. Masur H., Michelis M.A., Greene J.B. et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981; 305 (24): 1431–8. DOI: 10.1056/NEJM198112103052402
  4. Piot P., Quinn T.C., Taelman H. et al. Acquired immunodeficiency syndrome in a heterosexual population in Zaire. Lancet. 1984; 2 (8394): 65–9. DOI: 10.1016/s0140-6736(84)90241-1
  5. Van de Perre P., Rouvroy D., Lepage P. et al. Acquired immunodeficiency syndrome in Rwanda. Lancet. 1984; 2 (8394): 62–5. DOI: 10.1016/s0140-6736(84)90240-x
  6. Faria N.R., Rambaut A., Suchard M.A. et al. HIV Epidemiology. The early spread and epidemic ignition of HIV-1 in human populations. Science. 2014; 346 (6205): 56–61. DOI: 10.1126/science.1256739
  7. Smith D.M., Richman D.D., Little S.J. HIV superinfection. J Infect Dis. 2005; 192 (3): 438–44. DOI: 10.1086/431682
  8. UNAIDS (2015). AIDS by the numbers. Available at: http://www.unaids.org/en/resources/documents/2015/AIDS_by_the_numbers_2015 [Accessed 15.06.2020].
  9. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach (2013 version). Geneva, Switzerland: WHO Press; 2013.
  10. World Health Organization. Guidelines on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015. URL: http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/
  11. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, second edition, June 2016. URL: http://www.who.int/hiv/pub/arv/arv-2016/en/
  12. UNAIDS (2013). HIV in Asia and the Pacific. Available at: http://www.unaids.org/en/resources/documents/2013/20131119_HIV-Asia-Pacific
  13. Saravanan S., Velu V., Kumarasamy N. et al. Coinfection of hepatitis B and hepatitis C virus in HIV-infected patients in south India. World J Gastroenterol. 2007; 13 (37): 5015–20. DOI: 10.3748/wjg.v13.i37.5015
  14. Khalsa J.H., Elkashef A. Interventions for HIV and hepatitis C virus infections in recreational drug users. Clin Infect Dis. 2010; 50 (11): 1505–11. DOI: 10.1086/652447
  15. Becerra J.C., Bildstein L.S., Gach J.S. Recent Insights into the HIV/AIDS Pandemic. Microbial Cell. 2016; 3 (9): 451–75. DOI: 10.15698/mic2016.09.529
  16. Grulich A.E., Zablotska I. Commentary: probability of HIV transmission through anal intercourse. Int J Epidemiol. 2010; 39 (4): 1064–5. DOI: 10.1093/ije/dyq101
  17. Boily M.C., Baggaley R.F., Wang L. et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis. 2009; 9 (2): 118–29. DOI: 10.1016/S1473-3099(09)70021-0
  18. Keele B.F., Estes J.D. Barriers to mucosal transmission of immunodeficiency viruses. Blood. 2011; 118 (4): 839–46. DOI: 10.1182/blood-2010-12-325860
  19. Patel P., Borkowf C.B., Brooks J.T. et al. Estimating per-act HIV transmission risk: a systematic review. AIDS. 2014; 28 (10): 1509–19. DOI: 10.1097/QAD.0000000000000298
  20. Quinn T.C., Wawer M.J., Sewankambo N. et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000; 342 (13): 921–9. DOI: 10.1056/NEJM200003303421303
  21. Baeten J.M., Kahle E., Lingappa J.R. et al. Partners in Prevention HSVHIVTST Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011; 3 (77): 77ra29. DOI: 10.1126/scitranslmed.3001888
  22. Galvin S.R., Cohen M.S. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol. 2004; 2 (1): 33–42. DOI: 10.1038/nrmicro794
  23. Laga M., Piot P. Prevention of sexual transmission of HIV: real results, science progressing, societies remaining behind. AIDS. 2012; 26 (10): 1223–9. DOI: 10.1097/QAD.0b013e32835462b8
  24. Marrazzo J.M., Cates W. Interventions to prevent sexually transmitted infections, including HIV infection. Clin Infect Dis. 2011; 53 (Suppl. 3): S64–78. DOI: 10.1093/cid/cir695
  25. Chang L.W., Serwadda D., Quinn T.C. et al. Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects. Lancet Infect Dis. 2013; 13 (1): 65–76. DOI: 10.1016/S1473-3099(12)70273-6
  26. Volk J.E., Marcus J.L., Phengrasamy T. et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015; 61 (10): 1601–3. DOI: 10.1093/cid/civ778
  27. Coffin J., Swanstrom R. HIV pathogenesis: dynamics and genetics of viral populations and infected cells. Cold Spring Harb Perspect Med. 2013; 3 (1): a012526. DOI: 10.1101/cshperspect.a012526
  28. Stacey A.R., Norris P.J., Qin L. et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol. 2009; 83 (8): 3719–33. DOI: 10.1128/JVI.01844-08
  29. Pincus J.M., Crosby S.S., Losina E. et al. Acute human immunodeficiency virus infection in patients presenting to an urban urgent care center. Clin Infect Dis. 2003; 37 (12): 1699–704. DOI: 10.1086/379772
  30. Tokman S., Huang L. Evaluation of respiratory disease. Clin Chest Med. 2013; 34 (2): 191–204. DOI: 10.1016/j.ccm.2013.02.005
  31. Janoff E.N., Breiman R.F., Daley C.L. et al. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med. 1992; 117 (4): 314–24. DOI: 10.7326/0003-4819-117-4-314
  32. Hirschtick R.E., Glassroth J., Jordan M.C. et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med. 1995; 333 (13): 845–51. DOI: 10.1056/NEJM199509283331305
  33. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010; 85 (1): 1–18. DOI: 10.1016/j.antiviral.2009.10.002
  34. Kulpa D.A., Chomont N. HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide? J Virus Erad. 2015; 1 (2): 59–66.
  35. Guerrero M.L.F., Rivas P., Molina M. et al. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy. Clin Infect Dis. 2005; 41 (3): 390–4. DOI: 10.1086/431487
  36. Ford N., Calmy A., Hurst S. When to start antiretroviral therapy in resource-limited settings: a human rights analysis. BMC Int Health Hum Rights. 2010; 10: 6. DOI: 10.1186/1472-698X-10-6
  37. Deeks S.G. Determinants of virological response to antiretroviral therapy: Implications for long-term strategies. Clin Infect Dis. 2000; 30: S177–S184. DOI: 10.1086/313855
  38. Lee P.K., Kieffer T.L., Siliciano R.F. et al. HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother. 2006; 57 (5): 803–5. DOI: 10.1093/jac/dkl092
  39. Bertozzi S., Padian N.S., Wegbreit J. et al. HIV/AIDS Prevention and Treatment. Disease Control Priorities in Developing Countries. 2nd Ed. 2006; p. 331–69.
  40. Volk J.E., Marcus J.L., Phengrasamy T. et al. No New HIV Infections with Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting. Clin Infect Dis. 2015; 61 (10): 1601–3. DOI: 10.1093/cid/civ778
  41. Sabin C.A., Phillips A.N. Should HIV therapy be started at a CD4 cell count above 350 cells/mu l in asymptomatic HIV-1-infected patients? Curr Opin Infect Dis. 2009; 22 (2): 191–7. DOI: 10.1097/QCO.0b013e328326cd34
  42. Jain V., Deeks S.G. When to start antiretroviral therapy. Curr HIV/AIDS Rep. 2010; 7 (2): 60–8. DOI: 10.1007/s11904-010-0044-6
  43. Franco R.A., Saag M.S. When to start antiretroviral therapy: as soon as possible. BMC Med. 2013; 11: 147. DOI: 10.1186/1741-7015-11-148
  44. Lundgren J.D., Babiker A.G., Gordin F.M. et al. When to start antiretroviral therapy: the need for an evidence base during early HIV infection. BMC Med. 2013; 11: 148. https://doi.org/10.1186/1741-7015-11-148
  45. Group TAS: Danel C., Moh R., Gabillard D. et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015; 373 (9): 808–22. DOI: 10.1056/NEJMoa1507198
  46. Nachega J.B., Parienti J.J., Uthman O.A. et al. Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials. Clin Infect Dis. 2014; 58 (9): 1297–307. DOI: 10.1093/cid/ciu046
  47. May M.T., Gompels M., Delpech V. et al. Study UKCHC. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS. 2014; 28 (8): 1193–202. DOI: 10.1097/QAD.0000000000000243
  48. Liu C., Ma X., Liu B. et al. HIV-1 functional cure: will the dream come true? BMC Med. 2015; 13: 284. DOI: 10.1186/s12916-015-0517-y